Year All News202420232022202120202019201820172016 Jan 21 2019 ACHILLES THERAPEUTICS RECEIVES CTA APPROVAL FOR PHASE I/II STUDY IN NON-SMALL CELL LUNG CANCER — Ground-breaking clinical trial in patients with significant unmet medical need to start this year Read More + Dec 10 2018 ACHILLES THERAPEUTICS APPOINTS DR EDWIN MOSES AS CHAIRMAN OF ITS BOARD OF DIRECTORS AND DR IRAJ ALI AS CHIEF EXECUTIVE OFFICER Read More + Sep 19 2018 ACHILLES TODAY ANNOUNCES THAT IT HAS APPOINTED SENIOR PHARMACEUTICAL EXECUTIVE MICHAEL F. GIORDANO, M.D., TO ITS BOARD OF DIRECTORS. Read More + Apr 26 2017 ACHILLES’ FOUNDERS MAP TRUNCAL AND BRANCHED MUTATIONS AND COPY NUMBER EVENTS TO PREDICT EARLY RELAPSE IN NON-SMALL CELL LUNG CANCER. Read More + Jan 3 2017 ACHILLES STARTS 2017 WITH MOVE TO STEVENAGE BIOSCIENCE CATALYST Read More + Sep 28 2016 ACHILLES LAUNCHES WITH FUNDS OF £13.2M TO DEVELOP IMMUNOTHERAPIES FOR CANCER Read More + Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Current page 9
Jan 21 2019 ACHILLES THERAPEUTICS RECEIVES CTA APPROVAL FOR PHASE I/II STUDY IN NON-SMALL CELL LUNG CANCER — Ground-breaking clinical trial in patients with significant unmet medical need to start this year Read More +
Dec 10 2018 ACHILLES THERAPEUTICS APPOINTS DR EDWIN MOSES AS CHAIRMAN OF ITS BOARD OF DIRECTORS AND DR IRAJ ALI AS CHIEF EXECUTIVE OFFICER Read More +
Sep 19 2018 ACHILLES TODAY ANNOUNCES THAT IT HAS APPOINTED SENIOR PHARMACEUTICAL EXECUTIVE MICHAEL F. GIORDANO, M.D., TO ITS BOARD OF DIRECTORS. Read More +
Apr 26 2017 ACHILLES’ FOUNDERS MAP TRUNCAL AND BRANCHED MUTATIONS AND COPY NUMBER EVENTS TO PREDICT EARLY RELAPSE IN NON-SMALL CELL LUNG CANCER. Read More +